All consecutive patients with genetically confirmed PWS unselected for sleep-related symptoms, underwent a clinical interview, polysomnography, and multiple sleep latency tests (MSLT, n = 60), followed by long-term (24 hours) polysomnography (n = 22/60).
Results: Among 60 adults evaluated (57% female, aged 25 ± 10 years, body mass index: 39 ± 12 kg/m2), 67% reported excessive
sleepiness. According to the sleep study results, 43% had a previously unrecognized
hypersomnia disorder, 15% had an isolated sleep breathing disorder, 12% had combined
hypersomnia disorder and untreated breathing
sleep disorder, and only 30% had normal sleep. Isolated
hypersomnia disorder included
narcolepsy in 35% (type 1, n = 1, and type 2, n = 8),
hypersomnia in 12% (total sleep time >11 hours, n = 2, and MSLT <8 minutes, n = 1), and borderline phenotype in 53% (≥2 sleep onset in REM periods and MSLT >8 minutes, n = 10, and 8 minutes < MSLT < 10 minutes, n = 4). Sleep breathing disorders, isolated and combined, included
obstructive sleep apnea (n = 14, already treated in seven), sleep
hypoxemia (n = 1) and previously undiagnosed
hypoventilation (n = 5).
Modafinil was taken by 16 patients (well tolerated in 10), resulting in improved
sleepiness over a mean 5-year follow-up period.
Conclusion: